Immutep halted its Phase III TACTI‑004 trial of eftilagimod alfa (efti, IMP‑321) in first‑line non‑small‑cell lung cancer after an interim futility analysis, sending the company’s shares plummeting. The data monitoring committee recommended stopping the study per protocol; Immutep said it is analysing the dataset to understand the unexpected outcome. The stoppage ends the most advanced clinical test of the drug and raises immediate commercial and strategic questions for Immutep amid investor turmoil.